Kimberly Lynn Blackwell
Independent DirectorMs. Kimberly Lynn Blackwell, also known as Kim, M.D., is Chief Development Officer of Nucleus RadioPharma, Inc. from September 2025. She serves as an Lead Independent Director at Century Therapeutics, Inc. since March 2026. Ms. Blackwell is Independent Director at Incyclix Bio, LLC. from December 2025. Ms. Blackwell is Non-Executive Director of CHARM Therapeutics Inc. from September 2025. She is Director of Fore Biotherapeutics Inc. She has B.A. from Duke University, M.D. from Mayo Medical School. She is Director of Susan G. Komen for the Cure. She serves as Scientific Co-Founder at Cereius, Inc. She served as an Independent Director at Century Therapeutics, Inc. since June 2021. She has been an Independent Director at Monte Rosa Therapeutics, Inc. since July 2020 and also served as its Member of Scientific Advisory Board until December 2023. She served as Chief Medical Advisor at Tempus Labs, Inc. since May 2022 until April 2024 and had served as its Chief Medical Officer since March 2020 until May 16, 2022. From 2018 to 2020, she served as the Vice President of Early Stage Oncology and Immuno-oncology at Eli Lilly, where she led clinical teams advancing early phase therapeutics. She had been Director of Zentalis Pharmaceuticals, Inc. since July 1, 2020 until November 12, 2024. She served as Chief Executive Officer and President at Zentalis Pharmaceuticals, Inc. since May 10, 2022 until November 12, 2024. She served as a Member of Scientific Advisory Board at Zentalis Pharmaceuticals, Inc. She serves as Member of Scientific Advisory Board at Aravive, Inc. She was a professor of medicine and Assistant Professor of Radiation Oncology at Duke University Medical Center from 2000 to 2018 where she oversaw the women cancer program. Her clinical and research interests include various topics in breast cancer including endocrine therapy, novel HER2 therapies, breast cancer vaccines and other experimental therapeutics. She also served as the Co-Director of the Duke women’s cancer program, Associate Director for Strategic Relations for the Duke Cancer Institute, Research Scholar for Susan G. Komen and Senior Strategist for the Duke Innovation and Entrepreneurship Program from 2012 to 2018. She has studied and served as the principal investigator on studies that led to regulatory approval of four cancer agents, including the first biosimilar treatment for cancer in the United States. Due to her leadership, she has received numerous awards, including the Duke University Distinguished Alumni in 2015 and TIME Magazine’s 100 Most Influential People in the World in 2013. Additionally, she is a recipient of the Young Investigator Award in breast cancer from the National Cancer Institute Specialized Program of Research Excellence and the Joseph Greenfield Award for Mentorship of Clinical Research.
Positions
- Company NameMonte Rosa Therapeutics, Inc.Stock CodeGLUEPositionIndependent DirectorColleagues
- MWMarkus WarmuthPresident, CEO & Director
- ANAndrew Newman SchiffIndependent Chairman of the Board
- PNPhilip NicksonChief Business & Legal Officer
- FJFilip JankuChief Medical Officer
- MBMatthew BowenCorporate Controller & Principal Accounting Officer
- JCJennifer ChampouxChief Operating Officer
- KLKimberly Lynn BlackwellIndependent Director
- CEChristine E. SiuIndependent Director
- JSJan SkvarkaIndependent Director
- Company NameCentury Therapeutics, Inc.Stock CodeIPSCPositionLead Independent DirectorColleagues
- BPBrent PfeiffenbergerPresident, CEO & Chairman
- GRGregory RussottiChief Technology & Manufacturing Officer
- CAChad A. CowanChief Scientific Officer
- DCDouglas CarrSenior VP of Finance & Operations, Principal Financial Officer and Secretary
- KKKrista KauppinenVP, General Counsel & Head of Intellectual Property
- DEDaphne E. QuimiIndependent Director
- MPMartin Patrick MurphyIndependent Director
- JJJoseph JimenezSpecial Advisor to the Board
